Analysts’ Viewpoint on Pseudomonas Aeruginosa Infection Treatment Market Scenario
The pseudomonas aeruginosa infection treatment market is estimated to advance considerably during the forecast period due to an increase in occurrence of a wide range of infections globally. For instance, according to NCBI, high prevalence of pseudomonas aeruginosa infections is likely to cause a surge in the demand for treating pseudomonas aeruginosa infections in the next few years. The market grew during COVID-19, as some of the patients that underwent treatment in hospitals and other healthcare facilities for COVID-19 had acquired pseudomonas aeruginosa infections due to usage of ventilators and other medical devices. Therefore, pseudomonas aeruginosa infection treatment medications, such as oral ciprofloxacin which was used to treat the patients who had COVID-19, were also used to treat pseudomonas aeruginosa infections. Furthermore, according to the WHO reports, infections caused by pseudomonas aeruginosa carbapenem resistant strains have been listed under high risk category, which states that the need for treatment is projected to increase and consequently, boost the pseudomonas aeruginosa infection treatment market growth in the near future.
Pseudomonas aeruginosa is a type of bacteria that can cause infections in individuals after they undergo a surgery. Infection can occur in the blood, lungs, or other parts of the body. Pseudomonas aeruginosa infection treatment includes various medications, therapies, and procedures that can reduce the infection caused to an individual. Pseudomonas aeruginosa infection is generally treated through antibiotics and other drugs.
The global pseudomonas aeruginosa infection treatment market size is estimated to increase significantly during the forecast period owing to an increase in prevalence of pseudomonas aeruginosa, surge in awareness about the disease, adoption of expansion strategies, and robust pipeline of new therapeutic in clinical trials
Rise in prevalence of nosocomial infections associated with P. aeruginosa, such as pneumonia, urinary tract infections (UTI), cystic fibrosis, and blood stream infections, is likely to augment the global pseudomonas aeruginosa infection treatment market during the forecast period.
Increase in incidence of bacterial infections, i.e., Pseudomonas aeruginosa infections, in intensive care with no effective treatment is projected to drive the demand for newer antibacterial drugs and antibiotics for pseudomonas aeruginosa infection treatment.
According to Centers for Disease Control and Prevention (CDC) estimates, around 51,000 health care-associated P. aeruginosa infections occur in the U.S. each year. More than 6,000 (13%) of these are multidrug-resistant, with roughly 400 deaths per year attributed to these infections.
Antibacterial drug resistance is growing rapidly across the world, as it is in the nature of bacteria to develop resistance. This has generated the urgent need of new research and innovation in the antibacterial field.
According to U.S. Centers for Disease Control and Prevention (CDC) estimates, antibacterial resistance is responsible for over 2 million infections and 23,000 deaths in the U.S. each year and an estimated 25,000 deaths due to antibacterial-resistant infections in Europe. Hence, demand for newer broad spectrum antibacterial drugs is rising. There is always a need of antibacterial drugs for the treatment of children with fatal sepsis and severe pneumonia.
In terms of medication type, the global pseudomonas aeruginosa infection treatment market has been bifurcated into monotherapy and combination therapy. The combination therapy segment held around 74% of the global pseudomonas aeruginosa infection treatment market share in 2021. The segment is likely to maintain the status quo during the forecast period. The segment growth is due to increased drug resistance in monotherapy, which has resulted in a rise in the demand for combination therapy for the treatment of P. aeruginosa infection.
Combination therapy helps increase compliance, synergy, and efficacy, and reduce side-effects and cost. These factors are projected to boost the combination therapy segment. Additionally, rise in demand for combination therapy for treatment of pseudomonas aeruginosa infection is attributed to rapid onset of action, high bioavailability rate, cost saving, and high efficiency.
In terms of drug type, the global pseudomonas aeruginosa infection treatment market has been classified into aminoglycoside, cephalosporin, carbapenem, monobactam, and others.
The cephalosporin segment held a major share of around 40% in 2021. It is estimated to maintain the status quo during the forecast period. Expansion of the segment can be attributed to the focus of major pharmaceutical companies on the development of new class of cephalosporin for the treatment of various P. aeruginosa infections. This is expected to fuel the growth of the cephalosporin segment.
New cephalosporin (fifth-generation) was developed for the treatment of gram negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. Launch of new cephalosporin class of drugs is likely to boost the segment.
In terms of route of administration, the global pseudomonas aeruginosa infection treatment market has been split into nasal, oral, and intravenous.
The intravenous segment held a major share of around 40% in 2021. The segment is projected to grow and maintain its position during the forecast period due to the availability of the drugs for intravenous route, high accuracy in dosing, and rapid onset of action as compared to other routes.
Most physicians prefer intravenous route for administration of drugs because the entire administered dose reaches the systemic circulation, immediately, resulting in rapid onset of action against bacteria. This factor is expected to augment the segment.
In terms of distribution channel, the global pseudomonas aeruginosa infection treatment market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment held a major share of around 46% of the global market in 2021. The segment is projected to grow during the forecast period due to an increase in the number of multi-specialty hospitals in developing countries. Additionally, well-developed infrastructure and increase in adoption of new products by hospital pharmacies are likely to propel the segment during the forecast period.
Europe held a notable share of around 31% of the global pseudomonas aeruginosa infection treatment market, in terms of volume, in 2021. Europe is anticipated to account for a leading share of the global market during the forecast period, owing to an increase in the number of patients suffering from pseudomonas aeruginosa infection in the region.
North America held around 30% share of the global pseudomonas aeruginosa infection treatment market, in terms of value, in 2021. The market in the region grew at a notable growth rate due to a rise in aging population, highly structured health care industry, and availability of well-defined reimbursement policies from public and private health insurance firms, which are fueling the treatments for pseudomonas aeruginosa infection.
Middle East & Africa held a larger share of the global market as compared to that held by Latin America; however, the market in Latin America is estimated to rise at a higher growth rate as compared to the market in Middle East & Africa.
The pseudomonas aeruginosa infection treatment market report concludes with the company profiles section, which includes key information about major players in the global pseudomonas aeruginosa infection treatment market. The pseudomonas aeruginosa infection treatment market companies include ALLERGAN, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Co. and Janssen Pharmaceuticals, Inc.
Each of these players has been profiled in the pseudomonas aeruginosa infection treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 1.3 Bn |
|
Market Forecast Value in 2031 |
US$ 2.5 Bn |
|
Growth Rate (CAGR) for 2022-2031 |
6.6% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Example: Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global pseudomonas aeruginosa infection treatment market was valued at US$ 1.3 Bn in 2021
The global pseudomonas aeruginosa infection treatment market would surpass US$ 2.5 Bn by 2031
The global pseudomonas aeruginosa infection treatment market is anticipated to grow at a CAGR of 6.6% from 2022 to 2031
The combination therapy segment held over 74% share of the global pseudomonas aeruginosa infection treatment market in 2021
Europe is expected to hold a leading share of the global market during the forecast period
Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb Co., AstraZeneca., and Janssen Pharmaceuticals, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Pseudomonas Aeruginosa Infection Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Medication Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecasts, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Diseases Epidemiology
5.2. Pricing Analysis
5.3. Regulatory Scenario
5.4. Reimbursement Scenario by Region/globally
5.5. COVID-19 Impact Analysis
6. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Medication Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Medication Type, 2017 - 2031
6.3.1. Monotherapy
6.3.2. Combination Therapy
6.4. Market Attractiveness, by Medication Type
7. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Drug Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Type, 2017 - 2031
7.3.1. Aminoglycoside
7.3.2. Cephalosporin
7.3.3. Carbapenem
7.3.4. Monobactam
7.3.5. Others
7.4. Market Attractiveness, by Drug Type
8. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017 - 2031
8.3.1. Nasal
8.3.2. Oral
8.3.3. Intravenous
8.4. Market Attractiveness, by Route of Administration
9. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Medication Type, 2017 - 2031
11.2.1. Monotherapy
11.2.2. Combination Therapy
11.3. Market Value Forecast, by Drug Type, 2017 - 2031
11.3.1. Aminoglycoside
11.3.2. Cephalosporin
11.3.3. Carbapenem
11.3.4. Monobactam
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017 - 2031
11.4.1. Nasal
11.4.2. Oral
11.4.3. Intravenous
11.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017 - 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Medication Type
11.7.2. By Drug Type
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Medication Type, 2017 - 2031
12.2.1. Monotherapy
12.2.2. Combination Therapy
12.3. Market Value Forecast, by Drug Type, 2017 - 2031
12.3.1. Aminoglycoside
12.3.2. Cephalosporin
12.3.3. Carbapenem
12.3.4. Monobactam
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017 - 2031
12.4.1. Nasal
12.4.2. Oral
12.4.3. Intravenous
12.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country, 2017 - 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Medication Type
12.7.2. By Drug Type
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Medication Type, 2017 - 2031
13.2.1. Monotherapy
13.2.2. Combination Therapy
13.3. Market Value Forecast, by Drug Type, 2017 - 2031
13.3.1. Aminoglycoside
13.3.2. Cephalosporin
13.3.3. Carbapenem
13.3.4. Monobactam
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017 - 2031
13.4.1. Nasal
13.4.2. Oral
13.4.3. Intravenous
13.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country, 2017 - 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Medication Type
13.7.2. By Drug Type
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Medication Type, 2017 - 2031
14.2.1. Monotherapy
14.2.2. Combination Therapy
14.3. Market Value Forecast, by Drug Type, 2017 - 2031
14.3.1. Aminoglycoside
14.3.2. Cephalosporin
14.3.3. Carbapenem
14.3.4. Monobactam
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017 - 2031
14.4.1. Nasal
14.4.2. Oral
14.4.3. Intravenous
14.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country, 2017 - 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Medication Type
14.7.2. By Drug Type
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Medication Type, 2017 - 2031
15.2.1. Monotherapy
15.2.2. Combination Therapy
15.3. Market Value Forecast, by Drug Type, 2017 - 2031
15.3.1. Aminoglycoside
15.3.2. Cephalosporin
15.3.3. Carbapenem
15.3.4. Monobactam
15.3.5. Others
15.4. Market Value Forecast, by Route of Administration, 2017 - 2031
15.4.1. Nasal
15.4.2. Oral
15.4.3. Intravenous
15.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country, 2017 - 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Medication Type
15.7.2. By Drug Type
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Company Profiles
16.2.1. ALLERGAN
16.2.1.1. Company Description
16.2.1.2. Business Overview
16.2.1.3. Financial Overview
16.2.1.4. Strategic Overview
16.2.1.5. SWOT Analysis
16.2.2. Teva Pharmaceutical Industries Ltd.
16.2.2.1. Company Description
16.2.2.2. Business Overview
16.2.2.3. Financial Overview
16.2.2.4. Strategic Overview
16.2.2.5. SWOT Analysis
16.2.3. Pfizer Inc.
16.2.3.1. Company Description
16.2.3.2. Business Overview
16.2.3.3. Financial Overview
16.2.3.4. Strategic Overview
16.2.3.5. SWOT Analysis
16.2.4. Lupin Pharmaceuticals, Inc.
16.2.4.1. Company Description
16.2.4.2. Business Overview
16.2.4.3. Financial Overview
16.2.4.4. Strategic Overview
16.2.4.5. SWOT Analysis
16.2.5. AstraZeneca
16.2.5.1. Company Description
16.2.5.2. Business Overview
16.2.5.3. Financial Overview
16.2.5.4. Strategic Overview
16.2.5.5. SWOT Analysis
16.2.6. Merck & Co., Inc.
16.2.6.1. Company Description
16.2.6.2. Business Overview
16.2.6.3. Financial Overview
16.2.6.4. Strategic Overview
16.2.6.5. SWOT Analysis
16.2.7. Bristol-Myers Squibb Co.
16.2.7.1. Company Description
16.2.7.2. Business Overview
16.2.7.3. Financial Overview
16.2.7.4. Strategic Overview
16.2.7.5. SWOT Analysis
16.2.8. Janssen Pharmaceuticals, Inc.
16.2.8.1. Company Description
16.2.8.2. Business Overview
16.2.8.3. Financial Overview
16.2.8.4. Strategic Overview
16.2.8.5. SWOT Analysis
List of Tables
Table 01: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 02: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 03: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031
Table 05: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 08: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 09: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 10: North America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 13: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 14: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Europe Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 18: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 19: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 23: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 24: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Latin America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031
Table 28: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 29: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 30: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Pseudomonas Aeruginosa Infection Treatment Market, by Medication Type, 2021 and 2031
Figure 02: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031
Figure 03: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Monotherapy, 2017–2031
Figure 04: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Combination Therapy, 2017–2031
Figure 05: Global Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 06: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 07: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Aminoglycoside, 2017–2031
Figure 08: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Cephalosporin, 2017–2031
Figure 09: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Carbapenem, 2017–2031
Figure 10: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Monobactam, 2017–2031
Figure 11: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Others, 2017–2031
Figure 12: Global Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 13: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 14: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Nasal, 2017–2031
Figure 15: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Oral, 2017–2031
Figure 16: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Intravenous, 2017–2031
Figure 17: Global Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 18: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 19: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 20: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 21: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Online Pharmacies, 2017–2031
Figure 22: Global Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 23: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 24: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: North America Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 26: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 27: North America Pseudomonas Aeruginosa Infection Treatment Market, by Medication Type, 2021 and 2031
Figure 28: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031
Figure 29: North America Pseudomonas Aeruginosa Infection Treatment Market , by Drug Type, 2021 and 2031
Figure 30: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 31: North America Pseudomonas Aeruginosa Infection Treatment Market , by Route of Administration, 2021 and 2031
Figure 32: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 33: North America Pseudomonas Aeruginosa Infection Treatment Market , by Distribution Channel, 2021 and 2031
Figure 34: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 35: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 36: Europe Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 37: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 38: Europe Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 39: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031
Figure 40: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 41: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 42: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 43: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 44: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 45: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 46: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 48: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 49: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 50: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031
Figure 51: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 52: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 53: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 54: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 55: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 56: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Distribution Channel, 2022–2031
Figure 57: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 58: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 59: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 60: Latin America Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 61: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031
Figure 62: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 63: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 64: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 65: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 66: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 67: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 68: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 69: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 70: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 71: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 72: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031
Figure 73: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 74: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 75: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 76: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 77: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 78: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pseudomonas Aeruginosa Infection Treatment Market
